Abstract 2513
Background
We investigated whether Imunoscore performed on localized or locally advanced urothelial carcinoma (UC) tumor samples could predict response to neoadjuvant chemotherapy and survival outcome.
Methods
This retrospective ongoing study evaluated the Immunoscore in 150 patients with UC (140 UC of the bladder, 10 UC of the upper tract) from 6 centers (Greece and France). All patients underwent neo-adjuvant chemotherapy. Pre-treatment tumor samples (trans-urethral resection or upper tract biopsy) were immunostained for CD3+ and CD8+ T cells and quantified by digital pathology to determine the Immunoscore. The consensus Immunoscore was applied to tumors with invasive margin and an Immunoscore adapted to samples quantified when no invasion was identified on the specimen. Results were correlated with response to neoadjuvant treatment and time to recurrence (TTR).
Results
Immunoscore Low, Intermediate and High were respectively observed in 40, 43 and 17% of the cohort. Densities of CD3 and CD8 in the center and invasive margin were not significantly different according to clinical parameters such as T-stage, N-stage, age, gender, tumor differentiation (with or without variant), and localization (upper tract versus bladder). Immunoscore was positively and significantly correlated with TTR. High, intermediate and low Immunoscore patients had a median TTR of 83, 34 and 27 months, respectively (P < 0,05). In multivariate analysis, Immunoscore remains a significant independent parameter at presentation associated with TTR (High vs Low: P < 0.05). Immunoscore was positively and significantly correlated with pathologic complete response (pCR) (P < 0.001). Low Immunoscore was observed in 69% of patients with no pCR, and in only 20% of patients with pCR. In contrast, high Immunoscore was observed in only 7% of patients with no pCR, whereas 40% of these patients had a pCR.
Conclusions
The results of this ongoing study show a significant prognostic and potentially predictive role of Immunoscore in UC patients with important therapeutic implications. These preliminary results will be completed as samples are being analyzed before ESMO 2019 annual meeting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
FONCER.
Disclosure
C. Thibault: Honoraria (self), Travel / Accommodation / Expenses: Astellas Pharma; Honoraria (self): Ipsen; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen-Cilag; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Sanofi Pasteur; Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca/Medimmune; Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Roche/Genentech. F. Hermitte: Shareholder / Stockholder / Stock options, Full / Part-time employment: HalioDx. A. Bamias: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): Ipsen; Research grant / Funding (self): Lilly; Research grant / Funding (self): Astellas. J. Galon: Advisory / Consultancy, Research grant / Funding (institution), Shareholder / Stockholder / Stock options: HalioDx; Honoraria (self): AstraZeneca; Honoraria (self): Novartis; Honoraria (self): Merck; Honoraria (self): MSD; Honoraria (self): BMS; Honoraria (self): Sanofi; Honoraria (self): Gilead; Advisory / Consultancy, Research grant / Funding (institution): Io Biotech; Advisory / Consultancy: Illumina; Advisory / Consultancy: Northwest Biotherapeutics; Advisory / Consultancy: Actelion; Advisory / Consultancy: Amgen; Research grant / Funding (institution): Perkin Elmer; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Imcheck; Licensing / Royalties: INSERM. All other authors have declared no conflicts of interest.
Resources from the same session
3047 - Health-related quality of life in Greek haematogical malignancies patients undergoing chemotherapy
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract
1121 - Experiences of endocrine therapy after breast cancer surgery
Presenter: Susanne Ahlstedt Karlsson
Session: Poster Display session 3
Resources:
Abstract
2305 - The effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in breast cancer patients receiving adjuvant paclitaxel regimen: An-assessor blinded, three-arm randomized controlled trial
Presenter: Zehra Gok Metin
Session: Poster Display session 3
Resources:
Abstract
4561 - Agreement between breast cancer patients and oncologists on the severity of patients’ symptoms and functions during a one-year follow-up after treatment.
Presenter: Randi Reidunsdatter
Session: Poster Display session 3
Resources:
Abstract
1768 - Taste Changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Gulcan Bagcivan
Session: Poster Display session 3
Resources:
Abstract
1830 - CART-19: a comparative between literature versus experience
Presenter: Cassandra Andersson Vila
Session: Poster Display session 3
Resources:
Abstract
4027 - Unplanned emergency department use by people receiving ambulatory anti-cancer agents with potential febrile neutropenia
Presenter: Meritxell Casanovas-Blanco
Session: Poster Display session 3
Resources:
Abstract
4754 - Examining the benefits of medical exercise during radiotherapy in patients after mastectomy
Presenter: Nikolina Dodlek
Session: Poster Display session 3
Resources:
Abstract
2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC
Presenter: Qi Jiang
Session: Poster Display session 3
Resources:
Abstract
2989 - Adverse effects of chemotherapy influence the patients’ quality of life : Analysis of implicated factors
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract